logo-loader
viewShield Therapeutics PLC

Shield Therapeutics extends cash runway into 2021 after significant China deal

Proactive Research analyst Emma Ulker discusses Shield Therapeutics PLC's (LON:STX) 2019 business update and subsequent licence agreement for Feraccru/Accrufer with the integrated specialty pharma company Beijing Aosaikang Pharmaceutical Co Ltd (ASK Pharm) which covers China, Hong Kong, Macau and Taiwan. 

Ulker adds that a key highlight of 2019 included presentation of positive data from STX’s AEGIS head-to-head study of Feraccru vs the leading IV iron, Ferinject.

Click here to read Emma's note on Shield Therapeutics achieving significant milestones

Quick facts: Shield Therapeutics PLC

Price: 59.5 GBX

LSE:STX
Market: LSE
Market Cap: £69.98 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Shield Therapeutics: US commercial strategy for Accrufer and extension of...

Proactive analyst Emma Ulker discusses Shield Therapeutics PLC (LON:STX) which has updated on its commercialisation plan for the US market for its oral treatment Accrufer to treat iron deficiency.  While the company has engaged with a range of potential commercial partners for Accrufer,...

on 11/12/20

2 min read